glp 1 agonist trials GLP1 agonists: current and future landscape of clinical for patients with metabolic dysfunction GLP-1 receptor agonists are increasingly

Increasingly, obesity may be seen less as a personal failing and more as a medical condition, like type 2 diabetes or high cholesterol, warranting comprehensive treatment

Relevant to the subject, Sweden has a free prescription right which means that a prescriber can, at his or her own discretion but judging it based on scientific evidence and proven experience, circumvent, e.g., the approved indication and prescribe a drug outside of the specifications in the Summary of Product Characteristics (SmPC), i.e., off-label

Rim Masri, Faculty of Medical Sciences, Lebanese University, Hadath, Lebanon

Interest in ibogaine and related psychedelic-based therapeutics has increased significantly in recent years as researchers investigate their potential applications in addiction treatment, mental health disorders and neurological conditions

& Lacroix, A

The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugsTherapeutic potential exploration in lung injury